The first EU Joint Clinical Assessment is now a reality, and it is already offering valuable insights into how EU Health Technology Assessment Regulation may shape future evidence requirements, market access strategy, and local pricing and reimbursement decision-making.
Join Simon-Kucher experts for a focused webinar exploring the first JCA through the case of tovorafenib in paediatric low-grade glioma. Drawing on our in-depth reverse-engineering analysis, we will unpack how PICO scoping and evidence appraisal appear to work in practice, and what this means for manufacturers preparing for future EU HTA submissions.
Beyond the published report, the session will highlight the strategic implications for evidence planning, stakeholder engagement, and local P&R readiness in an evolving regulatory environment.
Participants will learn more about:
- How the assessment scope for tovorafenib was likely defined, including key considerations around PICO selection, comparator choice, and Member State perspectives
- How submitted evidence was appraised across PICOs, from study validity and comparator alignment to the handling of evidence gaps
- What the first JCA report means in practice for manufacturers preparing future HTA submissions
- Which methodological and procedural uncertainties remain, and how they could influence local pricing and reimbursement outcomes
- Practical steps manufacturers can take now to strengthen EU HTA readiness
Who should attend?
This webinar is free of charge and designed for Market Access, HEOR, and Commercial leaders navigating the evolving EU HTA Regulation landscape.
Attendees will leave with a clearer, expert-informed perspective on what the first EU JCA signals for the road ahead, and how to prepare with confidence.
Event details:
Tuesday, June 30, 2026: 3:00 - 4:00 p.m. CEST | 9:00 - 10:00 a.m. EDT
